SEARCH:   Advanced

Blood, 1 April 2007, Vol. 109, No. 7, pp. 2978-2981. Prepublished online as a Blood First Edition Paper on November 28, 2006; DOI 10.1182/blood-2006-07-033159. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-07-033159v1 109/7/2978    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Zhang, L. Articles by Su, L. Search for Related Content PubMed PubMed Citation Articles by Zhang, L. Articles by Su, L. Related Collections Immunobiology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY Brief Report HIV-1 infection and pathogenesis in a novel humanized mouse model Liguo Zhang1, Grigoriy I. Kovalev1, and Lishan Su1 1 Department of Microbiology and Immunology, The Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill The Rag2-C double-knockout (DKO) mouse lacks T, B, and natural killer (NK) cells, and allows development of a functional human immune system with human CD34+ hematopoietic stem/progenitor cells (DKO-hu HSCs). Normal human T, B, and dendritic cells are present in peripheral blood, thymus, spleen, and lymph nodes. We report that both CCR5 and CXCR4 are expressed on human immature and mature T cells. DKO-hu HSC mice allow efficient HIV-1 infection with plasma high viremia. High levels of productive infection occur in the thymus, spleen, and lymph nodes. Human CD4+ T cells are gradually depleted by HIV-1 in a dose-dependent manner. In addition, HIV-1 infection persists in infected DKO-hu HSC mice for at least 19 weeks, with infectious HIV-1 in lymphoid tissues. Thus, the DKO-hu HSC mouse can serve as a relevant in vivo model to investigate mechanisms of HIV-1 infection and immunopathogenesis as well as to develop anti–HIV-1 therapeutics. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R.-P. Sekaly The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J. Exp. Med., January 21, 2008; 205(1): 7 - 12. [Abstract] [Full Text] [PDF] S. Watanabe, S. Ohta, M. Yajima, K. Terashima, M. Ito, H. Mugishima, S. Fujiwara, K. Shimizu, M. Honda, N. Shimizu, et al. Humanized NOD/SCID/IL2R{gamma}null Mice Transplanted with Hematopoietic Stem Cells under Nonmyeloablative Conditions Show Prolonged Life Spans and Allow Detailed Analysis of Human Immunodeficiency Virus Type 1 Pathogenesis J. Virol., December 1, 2007; 81(23): 13259 - 13264. [Abstract] [Full Text] [PDF] M. Stevens, M. Pollicita, C. Pannecouque, E. Verbeken, O. Tabarrini, V. Cecchetti, S. Aquaro, C. F. Perno, A. Fravolini, E. De Clercq, et al. Novel In Vivo Model for the Study of Human Immunodeficiency Virus Type 1 Transcription Inhibitors: Evaluation of New 6-Desfluoroquinolone Derivatives Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1407 - 1413. [Abstract] [Full Text] [PDF] D. S. An, B. Poon, R. H. T. Fang, K. Weijer, B. Blom, H. Spits, I. S. Y. Chen, and C. H. Uittenbogaart Use of a Novel Chimeric Mouse Model with a Functionally Active Human Immune System To Study Human Immunodeficiency Virus Type 1 Infection Clin. Vaccine Immunol., April 1, 2007; 14(4): 391 - 396. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020